1.	General Evaluation
1.1	How would you rate this congress? (1=Poor 10=Excellent)
	1   2   3   4   5   6   7   8   9   10
1.2	Did this congress meet your expectations?      yes     no
1.3	Did this program prove useful to your work?
	extremely     somewhat     very little      not at all
1.4	Do you have any suggestions for next year’s congress?
1.5	Overall comments
2.	Plenary Sessions
2.1	How would you rate the First Plenary Session? (1=Poor 10=Excellent)
	1   2   3   4   5   6   7   8   9   10
2.2	How would you rate the Second Plenary Session? (1=Poor 10=Excellent)
	1   2   3   4   5   6   7   8   9   10
2.3	How would you rate the Third Plenary Session? (1=Poor 10=Excellent)
	1   2   3   4   5   6   7   8   9   10
2.4	Do you have any suggestions for next year’s Plenary Sessions topics?
2.5	Comments on the Plenary Sessions
3.	Issues Panels
	How would you rate the Issues Panels? (1=Poor 10=Excellent)
3.1	IP1: PAYOR ORIENTED EVIDENCE GUIDELINES
	1   2    3    4   5   6   7   8   9    10
3.2	IP2: MEMORY AND PERCEPTION: THE ISSUE OF RECALL BIAS IN PATIENT-REPORTED OUTCOMES
	1   2    3    4   5   6   7   8   9    10
3.3	IP3: SUBMISSION OF PATIENT-REPORTED OUTCOMES TO THE EMEA AND THE FDA: AREAS OF CONVERGENCE OR DIVERGENCE
	1   2    3    4   5   6   7   8   9    10
3.4	IP4: PROGRESS AND UNCERTAINTY IN HEALTH TECHNOLOGY ASSESSMENT
	1   2    3    4   5   6   7   8   9    10
3.5	IP5: EVALUATION OF DRUG SAFETY: CAN THE USE OF HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) METHODS PRODUCE BETTER DECISIONS?
	1   2    3    4   5   6   7   8   9    10
3.6	IP6: DO VACCINES RAISE ADDITIONAL ANALYTIC OR POLICY CHALLENGES?
	1   2    3    4   5   6   7   8   9    10
3.7	IP7: DO WE REALLY KNOW THE DIFFERENCE BETWEEN PROS AND QOL AND WHY IT'S IMPORTANT?
	1   2    3    4   5   6   7   8   9    10
3.8	IP8: 'FOURTH HURDLE' SYSTEMS: HOW WELL ARE THEY USING HTA IN DECISION-MAKING?
	1   2    3    4   5   6   7   8   9    10
3.9	IP9: THE QUALITY OF PHARMACO-ECONOMIC REIMBURSEMENT DOSSIERS
	1   2    3    4   5    6   7   8   9   10
3.10	Do you have any suggestions for future Issues Panel topics?
3.11	Comments on the Issues Panels
4.	Podium Presentations
4.1	In general, how would you rate the Podium Presentations? (1=Poor 10=Excellent)
	1   2   3   4   5   6   7   8   9   10
4.2	Were the speakers knowledgeable on their topics?	yes       no
4.3	Were there handouts/printed materials available?	yes       no
4.4	Were the visual presentations clear and easy to read?	yes       no
4.5	Please list any comments regarding Podium Presentations
5.	Poster Presentations
5.1	In general, how would you rate the Poster Presentations? (1=Poor 10=Excellent)
	1   2   3   4   6   7   8   9   10
5.2	Were there handouts/printed materials available?	yes       no
5.3	Were the visual presentations clear and easy to read?	yes       no
5.4	Please list any comments regarding Poster Presentations
6.	Workshop Presentations
6.1	In general, how would you rate the Workshop Presentations? (1=Poor 10=Excellent)
	1   2   3   4   5   6   7   8   9   10
6.2	Were speakers knowledgeable on their topics?	yes        no
6.3	Were there handouts/printed materials available?	yes        no
6.4	Were the visual presentations clear and easy to read?	yes        no
6.5	Which workshops did you attend?   Please list any comments regarding Workshop Presentations:
	W1: EXPOSURE PROPENSITY SCORES: CONCEPTS, APPLICATIONS, AND PRACTICAL CONSIDERATIONS      Please list any comments: W2: METHODS FOR MEDICATION COMPLIANCE STUDIES: PATIENT COMPLIANCE AS A PREDICTOR OF CLINICAL AND ECONOMIC OUTCOMES     Please list any comments: W3: METHODS FOR PRESENTING PROBABILISTIC SENSITIVITY ANALYSES FOR EFFECTIVE COMMUNICATION OF FINDINGS     Please list any comments: W4: CASE STUDIES IN PERSONALIZED MEDICINE: VALUE CREATION AND REWARDS--INCENTIVES AND IMPLICATIONS     Please list any comments: W5: MULTI-NATIONAL ASSESSMENT OF OUTCOMES VIA RETROSPECTIVE DATABASES     Please list any comments: W6: A NEW APPROACH TO HTA - A COMPUTERIZED MODEL     Please list any comments: W7: DISCRETE CHOICE EXPERIMENTS IN HEALTH POLICY AND DECISION MAKING     Please list any comments: mments: mments: W8: WHAT REALLY ARE PATIENT-REPORTED OUTCOMES?     Please list any comments: W9: META-ANALYSIS OF LONGITUDINAL DATA FOR ECONOMIC MODELS: AN APPLICATION OF MULTI-OUTCOME MODELS     Please list any comments: W10: INCORPORATING MEASURES OF COMPLIANCE AND PERSISTENCE IN PHARMACOECONOMIC EVALUATIONS     Please list any comments: mments: W11: THE ADDED VALUE OF BAYESIAN BELIEF NETWORKS FOR DECISION MAKING     Please list any comments: W12: MIXED TREATMENT COMPARISONS     Please list any comments: W13: PRICING POTENTIAL OF A NEW DRUG: APPLICATION OF THE PRICING MATRIX MODEL     Please list any comments: W14: KEY ISSUES IN MARKET ACCESS: FRANCE, SPAIN, AND ITALY     Please list any comments:   W15: CONJOINT ANALYSIS: APPLICATION TO GLOBAL PRICING AND REIMBURSEMENT STRATEGY     Please list any comments: W16: THE USE OF COMPOSITE ENDPOINTS: A REVIEW OF THE REGULATORS PERSPECTIVE AND METHODOLOGICAL ISSUES     Please list any comments: W17: THE USE OF HISTORICAL CONTROLS TO ENABLE ACTUAL PRACTICE COMPARISONS FOR PROSPECTIVE OBSERVATIONAL STUDIES     Please list any comments: W18: NON-COMPLIANCE WITH DRUG DOSING REGIMENS: AN UNDERESTIMATED BIAS IN DRUG TRIALS     Please list any comments: W19: CALCULATING STUDY POWER FOR ECONOMIC ANALYSES ALONGSIDE CLINICAL TRIALS     Please list any comments: W20: GLOBAL PRICING AND REIMBURSEMENT STRATEGY: AN INTEGRATED ANALYTICAL FRAMEWORK     Please list any comments: W21: PHARMACOECONOMICS AND MARKET ACCESS IN EUROPE: CASE STUDIES IN SCOTLAND AND THE NETHERLANDS     Please list any comments: W22: UNDERSTANDING INTERNATIONAL REQUIREMENTS WHEN DEVELOPING AND IMPLEMENTING A GLOBAL PATIENT REGISTRY: STRATEGIES TO MAXIMIZE SUCCESS     Please list any comments: W23: INTERNATIONAL ECONOMIC EVALUATIONS OF IMMUNISATION POLICIES: COMPARABILITY OF RESULTS AND CONCLUSIONS     Please list any comments: W24: RESCUING CLINICAL TRIAL DATA FOR ECONOMIC EVALUATION     Please list any comments: W25: CHALLENGES OF DESIGNING PROSPECTIVE AND RETROSPECTIVE COMPLIANCE STUDIES     Please list any comments: W26: DRG-BASED CASE COSTS: WHY THEY ARE NOT COMPARABLE ACROSS BORDERS AND SHOULD BE USED WITH CAUTION     Please list any comments: W27: METHODOLOGICAL CHALLENGES FOR COST-EFFECTIVENESS STUDIES FOR MEDICAL DEVICES     Please list any comments: W28: KEY ISSUES IN MARKET ACCESS: UK, SWEDEN, AND GERMANY     Please list any comments: W29: INTRODUCTION AND DIFFUSION OF INNOVATIVE INPATIENT DRUGS. COMBATING INEQUALITIES     Please list any comments: W30: THE VALUE OF CONJOINT ANALYSIS IN OUTCOMES RESEARCH     Please list any comments: W31: HEALTH STATUS AND QUALITY OF LIFE ASSESSMENT FOR CRITICAL DECISION MAKERS -- CLINICIANS, ADMINISTRATORS AND HEALTH ECONOMISTS    Please list any comments: W32: RISK ADJUSTMENT IN NON-COMPETITIVE MARKETS     Please list any comments:
7.	Program Personal Scheduler
7.1	Did you use the Online Personal Scheduler?	yes       no
7.2	Was it useful?	yes       no
7.3	Please list any suggestions regarding the Program Personal Scheduler
8.	Internet Stations
8.1	Did you use the internet stations provided at the Congress Center?	yes        no
8.2	Was there an acceptable amount of terminals available?	yes        no
8.3	Did the internet stations meet your needs during the congress?	yes        no
9.	Exhibition
9.1	How would you rate the exhibits? (1=poor 5=excellent)
	1     2     3     4     5
9.2	Were the exhibit hours long enough? (1=too short 5=too long)
	1     2     3     4     5
10.	ISPOR Professional Recruitment Assistance Program (PRAP) Center
10.1	Was the PRAP area useful? (1=not useful at all 5=very useful)
	1   2   3  4  5   N/A
11.	Congress  Management
11.1	Was the congress well run? (1=poor 5=excellent)
	1     2     3     4     5
11.2	Was the printed program clear and easy to follow? (1=poor 5=excellent)
	1     2     3     4     5
12.	Future ISPOR Conference and Congress
12.1	Do you plan to attend the ISPOR  2nd Asia-Pacific Conference to be held 5-7 March 2006 in Shanghai, China?
	yes      no      not sure
12.2	Do you plan to attend the ISPOR 11th Annual International Meeting to be held May 20-24, 2006 in Philadelphia, PA?
	yes      no      not sure
13.	Participant Information
13.1	Are you a:
	Registrant  Contributed paper presenter Media representative Exhibitor Other
13.2	What type of organization do you represent?
	Academic institution Consulting firm Contract research organization Diagnostic equipment manufacturer Government agency Hospital/medical Center Managed care organization Pharmaceutical company Pharmacy benefits management Other ( please specify)
13.3	How long have you been working in the field of pharmacoeconomics and outcomes research?
	less than 1 year 1-2 years 2-5 years 5-10 years 10-15 years 15-20 years more than 20 years
13.4	How many ISPOR European congresses have you attended before this one?
	none    1     2     3     4     5    6     7
13.5	How did you first hear of this congress?
	ISPOR Connections Conference Mailing Colleague Other  ( please specify)
13.6	Do you have any comments or suggestions for the ISPOR Ninth Annual European Congress?